Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 864

Sort by

Sort Order Select

Journal Articles

CD19.CAR T-cell–derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy

Blood Adv (2025) 9 (12): 2907–2919.

https://doi.org/10.1182/bloodadvances.2024014860

Published: 2025

Includes: Supplemental data

Journal Articles

Spatial transcriptomics of progression gene signature and tumor microenvironment leading to progression in mycosis fungoides

Myoung Eun Choi, Gyeonghoon Kim, Hwa-Jeong Shin, Chong Hyun Won, Sung Eun Chang, Mi Woo Lee, Woo Jin Lee

Blood Adv (2025) 9 (12): 2871–2885.

https://doi.org/10.1182/bloodadvances.2024014495

Published: 2025

Includes: Supplemental data

Journal Articles

AhR activation mitigates graft-versus-host disease of the central nervous system by reducing microglial NF-κB signaling

Blood Adv (2025) 9 (12): 2935–2952.

https://doi.org/10.1182/bloodadvances.2024015000

Published: 2025

Includes: Supplemental data

Journal Articles

Extracellular vesicles for CAR T-cell therapy immunomonitoring

Marion Klea Pinheiro, Benoît Vingert

Blood Adv (2025) 9 (12): 2920–2921.

https://doi.org/10.1182/bloodadvances.2025015988

Published: 2025

Journal Articles

Current developments in T-cell receptor therapy for acute myeloid leukemia

Sayali Gore, Emily Blyth, Marie Bleakley, Koon Lee, Kenneth Micklethwaite, Kavitha Gowrishankar

Blood Adv (2025) 9 (12): 3069–3089.

https://doi.org/10.1182/bloodadvances.2024014105

Published: 2025

Journal Articles

Adult thymectomy is associated with increased mortality risk from cancer but not cardiovascular disease

Kameron Allen Kooshesh, Brody Harry Foy, Richard A Baylis, Karin Gustafsson, Daniel A Zlotoff, Tomas G Neilan, David T Scadden

Blood Adv bloodadvances.2024015286.

https://doi.org/10.1182/bloodadvances.2024015286

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

Blood Adv (2025) 9 (11): 2763–2772.

https://doi.org/10.1182/bloodadvances.2024014846

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel

Blood Adv (2025) 9 (11): 2663–2676.

https://doi.org/10.1182/bloodadvances.2024013656

Published: 2025

Includes: Supplemental data

Journal Articles

Breaking the cycle: PRMTs and secondary HLH relief

Sakshi Malik, Shanmuganathan Chandrakasan

Blood Adv (2025) 9 (10): 2436–2437.

https://doi.org/10.1182/bloodadvances.2025015863

Published: 2025

Journal Articles

Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model

Wael Gamal, Nienke B. Goedhart, Helga Simon-Molas, Melanie Mediavilla-Varela, Angimar Uriepero-Palma, Fleur S. Peters, Kamira Maharaj, Julio C. Chavez, John Powers, Alyssa Obermayer, Timothy I. Shaw, José R. Conejo-Garcia, Paulo C. Rodriguez, Eva Sahakian, Javier Pinilla-Ibarz, Arnon P. Kater

Blood Adv (2025) 9 (10): 2511–2529.

https://doi.org/10.1182/bloodadvances.2024014822

Published: 2025

Includes: Supplemental data

Journal Articles

Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma

Sayalee V. Potdar, Shivani Kapadia, Maryam I. Azeem, Roman Radzievski, Kiran Lakhani, Nisha S. Joseph, Jonathan L. Kaufman, Craig C. Hofmeister, Vikas A. Gupta, Sagar Lonial, Ajay K. Nooka, Kavita M. Dhodapkar, Madhav V. Dhodapkar

Blood Adv (2025) 9 (10): 2438–2442.

https://doi.org/10.1182/bloodadvances.2024015680

Published: 2025

Includes: Supplemental data

Journal Articles

ATM inhibition decreases ERK activation and is synergistic with ibrutinib in primary chronic lymphocytic leukemia cells

Sara E. F. Kost, Ali Saleh, Jennifer Brown, Shek H. Yuan, Bozena Kuzio, Lin Yang, Versha Banerji, Spencer B. Gibson, James B. Johnston, Sachin Katyal

Blood Adv (2025) 9 (10): 2422–2427.

https://doi.org/10.1182/bloodadvances.2024014407

Published: 2025

Includes: Supplemental data

Journal Articles

PRMT5 inhibition reduces hyperinflammation in a murine model of secondary hemophagocytic lymphohistiocytosis

Blood Adv (2025) 9 (10): 2379–2392.

https://doi.org/10.1182/bloodadvances.2024013651

Published: 2025

Includes: Supplemental data

Journal Articles

Rituximab for children with EBV-positive Burkitt lymphoma in East Africa

Blood Adv (2025) 9 (10): 2393–2401.

https://doi.org/10.1182/bloodadvances.2024015234

Published: 2025

Includes: Supplemental data

Journal Articles

Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy

Snegha Ananth, Nancy Eunice Torres, Bita Sahaf, Lakha Mikkilineni, Sebastian Fernandez-Pol, Darren Salmi, Robert S. Negrin, Parveen Shiraz, Melody Smith, Sushma Bharadwaj, Wen-Kai Weng, Vanessa E Kennedy, Saurabh Dahiya, Lori S. Muffly, David B Miklos, Matthew J Frank, Hitomi Hosoya, Surbhi Sidana

Blood Adv bloodadvances.2025016346.

https://doi.org/10.1182/bloodadvances.2025016346

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement.

Blood Adv bloodadvances.2024015779.

https://doi.org/10.1182/bloodadvances.2024015779

Published: 2025

Journal Articles

Presentation of CXCL12γ by heparan sulfate proteoglycans activates CXCR4 without desensitization in normal and malignant B cells

Hildo C. Lantermans, Fangxue Ma, Annemieke Kuil, Martin F. M. de Rooij, Nick D. Bergkamp, Werner van der Meer, Jaap D. van Buul, Martine J. Smit, Marie José Kersten, Marcel Spaargaren, Steven T. Pals

Blood Adv (2025) 9 (9): 2307–2320.

https://doi.org/10.1182/bloodadvances.2024014396

Published: 2025

Includes: Supplemental data

Journal Articles

BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma

Katja Gutmair, Diego Villa, Nicholas Cunningham, Elisabeth Silkenstedt, Lisa Rimsza, Colleen Ramsower, David W. Scott, Alina S. Gerrie, Hanneke C. Kluin-Nelemans, Martin Dreyling, Eva Hoster

Blood Adv (2025) 9 (9): 2302–2306.

https://doi.org/10.1182/bloodadvances.2024015292

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 1 trial of durvalumab (anti–PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma

Christiane Querfeld, Joycelynne Palmer, Zhen Han, Xiwei Wu, Yate-Ching Yuan, Min-Hsuan Chen, Chingyu Su, Ni-Chun Tsai, D. Lynne Smith, Samantha N. Hammond, Liliana Crisan, Joo Y. Song, Raju Pillai, Steven T. Rosen, Jasmine Zain

Blood Adv (2025) 9 (9): 2247–2260.

https://doi.org/10.1182/bloodadvances.2024014655

Published: 2025

Includes: Supplemental data

Journal Articles

Neutrophil recruitment depends on platelet-derived leukotriene B4

Christian Hackenbroch, Tugce Cimen, Carina Gross, Stefanie Rubenzucker, Philipp Burkard, Niklas Groß, Robert Ahrends, Tamara Girbl, David Stegner

Blood Adv (2025) 9 (9): 2226–2230.

https://doi.org/10.1182/bloodadvances.2024014947

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CD19.CAR T-cell–derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy

Spatial transcriptomics of progression gene signature and tumor microenvironment leading to progression in mycosis fungoides

AhR activation mitigates graft-versus-host disease of the central nervous system by reducing microglial NF-κB signaling

Extracellular vesicles for CAR T-cell therapy immunomonitoring

Current developments in T-cell receptor therapy for acute myeloid leukemia

Adult thymectomy is associated with increased mortality risk from cancer but not cardiovascular disease

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel

Breaking the cycle: PRMTs and secondary HLH relief

Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model

Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma

ATM inhibition decreases ERK activation and is synergistic with ibrutinib in primary chronic lymphocytic leukemia cells

PRMT5 inhibition reduces hyperinflammation in a murine model of secondary hemophagocytic lymphohistiocytosis

Rituximab for children with EBV-positive Burkitt lymphoma in East Africa

Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy

Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement.

Presentation of CXCL12γ by heparan sulfate proteoglycans activates CXCR4 without desensitization in normal and malignant B cells

BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma

Phase 1 trial of durvalumab (anti–PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma

Neutrophil recruitment depends on platelet-derived leukotriene B4

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only